



Welcome iJOBS site visit to Novartis

Novartis Pharmaceuticals Corp.
August 11, 2025

 **NOVARTIS** | Reimagining Medicine

Opening remarks



Prof. Janet Alder, PhD

Assistant Dean for Graduate Academic and Student
Affairs, SGS
Assistant Vice Chancellor for Postdoctoral Affairs,
Rutgers Health
Associate Professor, Dept of Neuroscience & Cell
Biology, RWJMS
Rutgers University



John Sun, PhD, MBA, PMP

Program Lead
Global Clinical Operations
Development

iJOBS Novartis site visit agenda

Time	Location	Presenters	Agenda
12:45 – 1 pm	438 Cafeteria	John Sun , PhD, MBA, Global Program Lead, Global Drug Development	
1 – 2:30 pm	435 Labs	Michael Curto Anniesha Hack Tom Van Herwarde Stephen Hotra Steven McGrady	Pawan KC Arthi Krishnappa Will Ruezinsky Dattesh Suthar Lab Tour
2:30 – 2:40 pm	340-1310		<i>Walk to plenary session</i>
2:40 – 3:00 pm	340-1310	Stephen Eason , PhD, VP and Global Head Regulatory Writing & Submissions	Keynote
3:00 – 3:10 pm	340-1310	Chris Mellis , Early Career Business Partner	HR presentation
3:10 – 4:00 pm	340-1310	MaryLynn Mercado , PhD, Global Head Protocol Delivery and US Site Head RWS Cecilia Nunes , PhD, Senior Expert, Science & Technology, Process Development Cell Therapies Jorge Safi , MD, PhD, VP, Patient Safety Development Unit Head, Cardio Renal Metabolism Gangadhar Sunkara , PhD, Global Program Head, In-Market Brand and Global Health	Panel Discussion

Keynote: Reimagining medicine, together



Stephen Eason, PhD

Vice President and Global Head
Regulatory Writing & Submissions

Novartis is an innovative medicines company

Novartis consistently ranks among the world's top companies investing in R&D.¹

USD 8.6 bn
Core R&D spend in 2023²




USD 45.4 bn
Net sales in 2023

¹ All figures refer to continuing operations (i.e. excluding Sandoz).

² This presentation includes non-IFRS financial measures such as constant currencies and core R&D spend. A definition of non-IFRS measures used by Novartis, and further details, including reconciliation tables, can be found in "Item 5. Operating and Financial Review and Prospects" of the Novartis Annual Report 2023.

Our transformation

Over the years we have transformed from a healthcare conglomerate to an innovative medicines company, culminating in the spin-off of our Sandoz generics and biosimilars business in October 2023.



Our purpose and vision are supported by a strong culture with clear values



Purpose

Reimagine medicine to improve and extend people's lives



Vision

To become the most valued and trusted medicines company in the world



Values and behaviors

Inspired. Curious. Unbossed. Integrity



Millions of people worldwide benefit from our medicines


130



Countries

where Novartis medicines are distributed¹

284 m



Patients reached

with our medicines

All figures refer to continuing operations (i.e. excluding Sandoz).

We operate in a world where powerful forces are transforming healthcare

Accelerating innovation in science and technology



Aging-related rise in chronic diseases



Health inequities remain entrenched



Our strategy

Deliver high-value medicines that alleviate society's greatest disease burdens through technology leadership in R&D and novel access approaches

Our focus

Core therapeutic areas¹

Cardiovascular, renal and metabolic; immunology; oncology; and neuroscience



Technology platforms

Chemistry; biotherapeutics; xRNA; radioligand; gene and cell therapy



4 priority markets

US, Germany, China, Japan



Our priorities

Accelerate growth

Deliver **high-value medicines**



Deliver returns

Embed **operational excellence**



Strengthen foundations

Unleash the power of our **people**

Scale **data science and technology**

Build trust with **society**



1. Other TAs opportunistically.

Deliver high-value medicines

We are dedicated to discovering and developing new treatments for diseases including cancer, heart disease and neurological conditions — and delivering them at scale to reach as many patients as possible

Highlights | 2023

USD 8.6 bn

Core R&D spend

41

ongoing Phase III programs

22

approvals
(US, EU, Japan, China)

18 000+


employees working
in R&D

18

submissions
(US, EU, Japan, China)

USD 98.4 m

invested in R&D for malaria and neglected tropical diseases



All figures refer to continuing operations (i.e. excluding Sandoz).

Embed operational excellence

We aim to drive efficiency and free up resources to invest in innovation for patients. In everything we do, we maintain high standards of patient safety, while also working to reduce our environmental footprint

Highlights | 2023

19.8 bn

treatments sold to third parties



63%

reduction in greenhouse gas emissions in our own operations since 2016



50%

reduction in water consumption in our own operations since 2016



All figures the refer to continuing operations (i.e. excluding Sandoz).

Strengthen our foundations

Unleash the power of our people



We are investing in our culture to empower every Novartis employee to be inspired by our purpose and drive innovation

Scale data science and technology



We use data science and technology to find new ways to treat disease, improve our operations and support patients and healthcare professionals

Build trust with society



We aim to make our medicines available to as many people as possible around the world and follow high standards of ethical behavior wherever we operate

Highlights | 2023

78 000+ Employees

48% Women in management

140+ Nationalities

250+

specialist data scientists embedded within research project teams to help optimize and accelerate key aspects of our research

186%

increase in patients reached with our strategic innovative therapies in LMICs since 2019

97%

of employees trained and certified on our Code of Ethics

All figures the refer to continuing operations (i.e. excluding Sandoz).

Our achievements are gaining recognition

Access to Medicine Index

Novartis has ranked in the leadership group for more than 10 years

Bloomberg Gender Equality Index

Novartis was included in 2023 for the fourth year in a row

CDP

Novartis achieved Double A List status in Climate Change and Water Security (based on latest available results from 2022)

MSCI

Novartis maintained its AA rating in the 2023 MSCI ESG Ratings assessment.

1. All information based on 2023 data.

Our medicines

Our medicines treat major diseases, from cancer and heart disease to rare genetic disorders

We focus on four core therapeutic areas with high unmet patient need



Cardiovascular, renal & metabolic



Immunology



Neuroscience



Oncology

In addition, we have research and in-market programs in:



Ophthalmology



Respiratory



Global health

Top 10 innovative medicines

by 2023 net sales



Entresto®

An oral medicine for heart failure and hypertension



Cosentyx®

An injectable treatment for several systemic inflammatory conditions



Promacta® / Revolade® An oral treatment for certain blood disorders



Kesimpta®

Injectable treatment for relapsing multiple sclerosis



Kisqali®

An oral treatment for a type of breast cancer



Tafinlar® + Mekinist® An oral combination therapy for certain types of skin, thyroid and lung cancers



Tassigna®

An oral treatment for a type of chronic myeloid leukemia



Jakavi®

An oral therapy for certain rare blood disorders



Lucentis®

An injectable medicine for certain conditions of the retina



Xolair®

An injectable therapy for certain respiratory and immunological conditions, including severe allergic asthma

Values and Behaviors

Values and Behaviors

We all have a role to play in shaping the culture we want to see. Behaviors in Action and Leader Expectations provide a practical guide for our people and leaders respectively to think, act, and make decisions every day in line with our values.



Inspired

- Engage our people
- Strive for patients
- Live our purpose



Curious

- Learn
- Be open
- Be self-aware



Unbossed

- Create clarity
- Serve others
- Own your actions





Integrity

- Be honest
- Have courage
- Do what's right

Drug development processes overview



Development process at a glance



Thank you



Career at Novartis



Chris Mellis
Early Career Business Partner


Your career path @ Novartis

- Visit our Career site: www.novartis.com/careers
- Keyword Search, Employment Type and Location
- Job Search Alert: get updates on job postings that match your criteria
- Join our Talent Network: https://talentnetwork.novartis.com/en_US/network

Familiarize yourself with:

- Our Mission, Culture and Strategic Priorities
- Our Disease Areas

Career opportunities @ Novartis



Welcome to where we thrive together

Improving the lives of people living with disease takes more than innovative science. It takes a focus on the needs of people and a community committed to meeting them. It takes a team of people like you. Working together. Learning together. Thriving together. Discover how you can join us in changing people's lives.

Join the Novartis Network!



- Stay connected for news, events, career opportunities and exclusive updates from our people about what it's really like to work with Novartis.
- Helping people with disease and their families takes more than innovative science, it takes a team of people like you. We're a community of dedicated and smart people united by a drive to achieve together. And, whatever your role, you'll be inspired and propelled by those beside you.
- We strive to ensure that people of all backgrounds and experiences can feel at home. Here, differences are not only welcomed but celebrated, and people are recognized for who they are as much as for what they do.

Job postings (including interns)

Home > Careers > Career Search

Career Search

Explore opportunities with Novartis below.

Notice to applicants for US job openings. [Learn More](#)

Search Jobs Function (f) Location (l)

Division Date Posted

USA

Showing 140 results

All US jobs

Job Title	Business	Location	Site	Date Posted
Executive Assistant to Global Head, PK Sciences Regular, Full time	Universal Hierarchy Node	USA	Cambridge (USA)	Aug 04, 2025
Senior People Partner Regular, Full time	Universal Hierarchy Node	USA	Cambridge (USA)	Aug 03, 2025
Clinical Development Director Regular, Full time	Universal Hierarchy Node	USA	East Hanover	Aug 01, 2025
Senior Clinical Research Associate (Remote Position) Regular, Full time	Universal Hierarchy Node	USA	Field Non-Sales (USA)	Jul 30, 2025
Senior Clinical Research Associate (Remote Position) Regular, Full time	Universal Hierarchy Node	USA +Alternative Locations	Field Non-Sales (USA)	Jul 30, 2025
Clinical Research Associate/Senior Clinical Research Associate (Remote)	Universal Hierarchy Node	USA	Field Non-Sales (USA)	Jul 30, 2025

Opportunities for students and graduates

Whether you join us on an internship, after graduating or from another role, we offer you the chance to build connections and expertise at the cutting edge of medicines.



Students

Still studying? With Novartis, you can feel excited about building a future before your career even begins.



Graduates

Join Novartis as a graduate for a chance to develop your expertise within a fast-paced, global environment built on continuous growth.



Early in Career Professionals

Bring your 2-5 years' experience to Novartis and shape the future of healthcare through innovation and transformative projects.

Our application process



Application

Apply online and we'll aim to process your application as soon as possible, communicating with you every step of the way.



Screening

At this stage, we're looking to confirm your suitability for the role. This is likely to involve a preliminary interview with your recruiter or hiring manager.



Interview

Your main interview could involve a mixture of virtual and in-person elements and may include relevant assessment exercises as well as an opportunity to connect with some key peers and stakeholders.



Offer

If you're successful, we'll make you a verbal offer. Once you've accepted, we'll start preparing for your first day. Congratulations, we're delighted to have you as part of our team!

Thank you



Panel Discussion

MaryLynn Mercado, PhD

Global Head Protocol Delivery and US Site Head RWS

Cecilia Nunes, PhD

Senior Expert, Science & Technology, Process Development Cell Therapies

Jorge Safi, MD, PhD

VP, Patient Safety Development Unit Head, Cardio Renal Metabolism

Gangadhar Sunkara, PhD

Global Program Head, In-Market Brand and Global Health

Panel Discussion



MaryLynn Mercado, PhD
Global Head Protocol
Delivery and US Site Head
RWS



Cecilia Nunes, PhD
Senior Expert, Science
& Technology, Process
Development Cell
Therapies



Jorge Safi, MD, PhD
VP, Patient Safety
Development Unit Head,
Cardio Renal Metabolism



Gangadhar Sunkara, PhD
Global Program Head, In-
Market Brand and Global
Health

Questions to the panels

- Tell your story in terms of your career trajectory and your current job description. What your typical day is like.
- Describe any jobs in your area that might be different than the four of yours for people with a PhD.
- Come up with some suggestions on how to prepare yourself for a career in your field prior to applying.
- Suggest the best steps to take to get a job in your field.

Questions and Answers

 **NOVARTIS** | Reimagining Medicine

